Secondary diffuse large B-cell lymphoma of the central nervous system: the need for better predictors.

about

Secondary diffuse large B-cell lymphoma of the central nervous system: the need for better predictors.

Item

http://www.wikidata.org/entity/Q53458657

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Secondary diffuse large B-cell ...... he need for better predictors.

@en

Secondary diffuse large B-cell ...... he need for better predictors.

@nl

type

Item

label

Secondary diffuse large B-cell ...... he need for better predictors.

@en

Secondary diffuse large B-cell ...... he need for better predictors.

@nl

prefLabel

Secondary diffuse large B-cell ...... he need for better predictors.

@en

Secondary diffuse large B-cell ...... he need for better predictors.

@nl

P1476

Secondary diffuse large B-cell ...... he need for better predictors.

@en

P2093

Kieron Dunleavy

http://www.w3.org/2001/XMLSchema#string

Mark Roschewski

http://www.w3.org/2001/XMLSchema#string

P2860

Aggressive lymphomas

Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.

Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.

Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.

Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.

Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.

CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.

P304

1583-1584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2015.1016936

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26099732

http://www.w3.org/2001/XMLSchema#string